Cargando…

Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System

SIMPLE SUMMARY: We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordgård, Oddmund, Brendsdal Forthun, Rakel, Lapin, Morten, Grønberg, Bjørn Henning, Kalland, Karl Henning, Kopperud, Reidun Kristin, Thomsen, Liv Cecilie Vestrheim, Tjensvoll, Kjersti, Gilje, Bjørnar, Gjertsen, Bjørn Tore, Hovland, Randi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069797/
https://www.ncbi.nlm.nih.gov/pubmed/33924696
http://dx.doi.org/10.3390/cancers13081861
_version_ 1783683321351372800
author Nordgård, Oddmund
Brendsdal Forthun, Rakel
Lapin, Morten
Grønberg, Bjørn Henning
Kalland, Karl Henning
Kopperud, Reidun Kristin
Thomsen, Liv Cecilie Vestrheim
Tjensvoll, Kjersti
Gilje, Bjørnar
Gjertsen, Bjørn Tore
Hovland, Randi
author_facet Nordgård, Oddmund
Brendsdal Forthun, Rakel
Lapin, Morten
Grønberg, Bjørn Henning
Kalland, Karl Henning
Kopperud, Reidun Kristin
Thomsen, Liv Cecilie Vestrheim
Tjensvoll, Kjersti
Gilje, Bjørnar
Gjertsen, Bjørn Tore
Hovland, Randi
author_sort Nordgård, Oddmund
collection PubMed
description SIMPLE SUMMARY: We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further integration of liquid biopsy methods in clinical practice are discussed, with a special focus on a Nordic Healthcare system. ABSTRACT: Liquid biopsies have emerged as a potential new diagnostic tool, providing detailed information relevant for characterization and treatment of solid cancers. We here present an overview of current evidence supporting the clinical relevance of liquid biopsy assessments. We also discuss the implementation of liquid biopsies in clinical studies and their current and future clinical role, with a special reference to the Nordic healthcare systems. Our considerations are restricted to the most established liquid biopsy specimens: circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Both ctDNA and CTCs have been used for prognostic stratification, treatment choices, and treatment monitoring in solid cancers. Several recent publications also support the role of ctDNA in early cancer detection. ctDNA seems to provide more robust clinically relevant information in general, whereas CTCs have the potential to answer more basic questions related to cancer biology and metastasis. Epidermal growth factor receptor-directed treatment of non-small-cell lung cancer represents a clinical setting where ctDNA already has entered the clinic. The role of liquid biopsies in treatment decisions, standardization of methods, diagnostic performance and the need for further research, as well as cost and regulatory issues were identified as factors that influence further integration in the clinic. In conclusion, substantial evidence supports the clinical utility of liquid biopsies in cancer diagnostics, but further research is still required for a more general application in clinical practice.
format Online
Article
Text
id pubmed-8069797
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80697972021-04-26 Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System Nordgård, Oddmund Brendsdal Forthun, Rakel Lapin, Morten Grønberg, Bjørn Henning Kalland, Karl Henning Kopperud, Reidun Kristin Thomsen, Liv Cecilie Vestrheim Tjensvoll, Kjersti Gilje, Bjørnar Gjertsen, Bjørn Tore Hovland, Randi Cancers (Basel) Review SIMPLE SUMMARY: We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further integration of liquid biopsy methods in clinical practice are discussed, with a special focus on a Nordic Healthcare system. ABSTRACT: Liquid biopsies have emerged as a potential new diagnostic tool, providing detailed information relevant for characterization and treatment of solid cancers. We here present an overview of current evidence supporting the clinical relevance of liquid biopsy assessments. We also discuss the implementation of liquid biopsies in clinical studies and their current and future clinical role, with a special reference to the Nordic healthcare systems. Our considerations are restricted to the most established liquid biopsy specimens: circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Both ctDNA and CTCs have been used for prognostic stratification, treatment choices, and treatment monitoring in solid cancers. Several recent publications also support the role of ctDNA in early cancer detection. ctDNA seems to provide more robust clinically relevant information in general, whereas CTCs have the potential to answer more basic questions related to cancer biology and metastasis. Epidermal growth factor receptor-directed treatment of non-small-cell lung cancer represents a clinical setting where ctDNA already has entered the clinic. The role of liquid biopsies in treatment decisions, standardization of methods, diagnostic performance and the need for further research, as well as cost and regulatory issues were identified as factors that influence further integration in the clinic. In conclusion, substantial evidence supports the clinical utility of liquid biopsies in cancer diagnostics, but further research is still required for a more general application in clinical practice. MDPI 2021-04-13 /pmc/articles/PMC8069797/ /pubmed/33924696 http://dx.doi.org/10.3390/cancers13081861 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nordgård, Oddmund
Brendsdal Forthun, Rakel
Lapin, Morten
Grønberg, Bjørn Henning
Kalland, Karl Henning
Kopperud, Reidun Kristin
Thomsen, Liv Cecilie Vestrheim
Tjensvoll, Kjersti
Gilje, Bjørnar
Gjertsen, Bjørn Tore
Hovland, Randi
Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
title Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
title_full Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
title_fullStr Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
title_full_unstemmed Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
title_short Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
title_sort liquid biopsies in solid cancers: implementation in a nordic healthcare system
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069797/
https://www.ncbi.nlm.nih.gov/pubmed/33924696
http://dx.doi.org/10.3390/cancers13081861
work_keys_str_mv AT nordgardoddmund liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT brendsdalforthunrakel liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT lapinmorten liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT grønbergbjørnhenning liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT kallandkarlhenning liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT kopperudreidunkristin liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT thomsenlivcecilievestrheim liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT tjensvollkjersti liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT giljebjørnar liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT gjertsenbjørntore liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem
AT hovlandrandi liquidbiopsiesinsolidcancersimplementationinanordichealthcaresystem